Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated weith ropinirole or levodopa

Article Abstract:

The drug ropinirole appears to be as effective as levodopa for treating Parkinson's disease and has fewer side effects. Ropinirole stimulates the dopamine D2 receptor, which is important because Parkinson's disease is partly caused by a dopamine deficiency. Researchers randomly assigned 268 patients with Parkinson's disease to take the traditional treatment, a drug called levodopa, or ropinirole. Only half the patients in both groups completed the five-year study. Ropinirole was as effective in alleviating symptoms as levodopa and only 20% of the patients taking it developed dyskinesia, compared to 45% of those taking levodopa. Dyskinesia is a side effect of some drugs.

Author: Rascol, Olivier, Brooks, David J., Korczyn, Amos D., De Deyn, Peter P., Clarke, Carl E., Lang, Anthony E.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000
Prevention, Movement disorders

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease

Article Abstract:

The drug clozapine appears to be effective for reducing the side effects of medication used to treat Parkinson's disease. These medications often cause psychotic symptoms in patients with Parkinson's disease. Researchers randomly assigned 60 patients with Parkinson's disease to take clozapine or a placebo for up to 14 months. All of the patients took their regular dose of medication for Parkinson's disease. Those who took clozapine experienced a reduction in psychotic symptoms compared to those who took a placebo. Clozapine also reduced the tremor associated with Parkinson's disease.

Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1999
Evaluation, Clozapine

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Levodopa and the progression of Parkinson's disease

Article Abstract:

A study is undertaken to assess the effect of levodopa on the rate of progression of ParkinsonEs disease. The clinical data suggested that levodopa either slows the progression of Parkinson's disease or has a prolonged effect on the symptoms of the disease.

Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
England, Care and treatment, Influence, Dopa, L-dopa

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Drug therapy, Parkinson's disease, Parkinson disease
Similar abstracts:
  • Abstracts: Making sense of ...parenteral nutrition in adult patients. Making sense of bowel preparation. Making sense of the care of patients with pancreatitis
  • Abstracts: Effect of ramipril on the incidence of diabetes. ACE inhibition in cardiovascular disease. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
  • Abstracts: Effect of supplementation of smoking men with plain or slow release ascorbic acid on lipoprotein oxidation. Low serum folate concentrations are associated with an excess incidence of acute coronary events: The Kuopion Ischaemic Heart Disease Risk Factory Study
  • Abstracts: Association of tuberculosis infection with increased time in or admission to the New York City jail system. HIV-Related Tuberculosis in a Transgender Network--Baltimore, Maryland, and New York City Area, 1998-2000
  • Abstracts: Elective acquaints medical students with abortion. Direct observation of community-based ambulatory encounters involving medical students
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.